ClinicalTrials.gg
CompletedNCT01111461Updated Jun 22, 2023Results posted

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

A Phase 2 interventional study of Lenvatinib in Endometrial Cancer, sponsored by Eisai Inc.. Completed at 79 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
133
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing lenvatinib in Endometrial Neoplasms — 4 open to participants now, 6 under way, none of them phase 3. lenvatinib · Endometrial Neoplasms.

Enrollment
3rd of 15
133 · median 32
Started
2010
the only one that year
Phase 2
6 of 15
1 open now
Registered
1st of 15
by date
Lead sponsor
2 of 15
Eisai Inc.

Among the 15 studies testing lenvatinib in Endometrial Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2010, is one of 6 in phase 2, and was the 1st registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 15 studies testing lenvatinib in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 355 Endometrial Neoplasms studies recruiting now, 265 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing lenvatinib in Endometrial Neoplasms, or all of them as a file.
02

Study summary

To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Advanced Endometrial Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of endometrial carcinoma.
  2. Radiographic evidence of disease progression according to modified 1.1 after 1 prior systemic, platinum-based chemotherapy regimen for recurrent or primary unresectable endometrial carcinoma for which no surgical or radiotherapy treatment option exists.
  3. Measureable disease meeting the following criteria:

    • At least 1 lesion of greater than 1.0 cm in the longest diameter for a non-lymph node or greater than 1.5 cm in the short-axis diameter for a lymph node which is serially measureable according to modified RECIST 1.1 using computerized tomography / magnetic resonance imaging.
    • Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency ablation must show evidence of progressive disease based on modified RECIST 1.1 to be deemed a target lesion.
  4. (ECOG) performance status less than 2.
  5. Adequate controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Screening Visit.
  6. Adequate renal function defined as calculated greater than 30 mL/min per the Cockcroft and Gault formula.
  7. Adequate bone marrow, blood coagulation, and liver functions, as defined in the study protocol.
  8. Negative serum or urine pregnancy test for women of .

Exclusion criteria

Exclusion criteria:

  1. Brain or , including stable .
  2. More than 1 prior systemic chemotherapy regimen for recurrent metastatic or primary unresectable endometrial carcinoma or any treatment targeting vascular endothelial growth factor (VEGF)-directed angiogenesis. No restriction regarding prior chemotherapy or hormonal therapy.
  3. Prior systemic anti-tumor therapy within 3 weeks.
  4. Not fully recovered from prior radiotherapy based on investigator judgement.
  5. Participants with greater than 1+ proteinuria on urine dipstick testing to undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with greater than 1 gm will be ineligible.
  6. Significant cardiovascular impairment: history of congestive heart failure greater than Class II; unstable angina; myocardial infarction or stroke within 6 months of the first dose of study drug; cardiac arrhythmia requiring medical treatment.
  7. Prolongation of greater than 480 msec.
  8. Bleeding disorder or thrombotic disorders requiring anticoagulant therapy, such as warfarin, or similar agents requiring therapeutic monitoring (treatment with low molecular weight heparin [LMWH] allowed).
  9. Active hemoptysis within 3 weeks prior to the first dose of study drug.
  10. Females who are pregnant or breast feeding.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Lenvatinib 24 mg

    Participants with advanced endometrial cancer and disease progression following platinum-based, first line chemotherapy.

    Drug: Lenvatinib

Interventions

  • Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.

    Also known as: E7080, Lenvima

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for target lesions assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans, as determined by independent radiologic review. BOR of CR was confirmed by a subsequent CR assessment at least 4 weeks later. BOR of PR was confirmed by a subsequent CR or PR assessment at least 4 weeks later. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters. The null hypothesis ORR was ≤10% was tested using 1-sided exact test of a single proportion, at 1-sided 0.05 level. ORR was presented with corresponding 2-sided, 95% confidence interval (CI). ORR=CR+PR

    Time frame: From the date of first administration of study treatment until all participants completed a minimum of 6 cycles (28-day cycles) or discontinued treatment prior to the end of Cycle 6 (as of 21 May 2012 data cut-off)

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was measured as the time from the date of first administration of study treatment until the date of first documentation of disease progression or date of death (whichever occurred first), as determined by independent radiologic review (IRR) and Investigator based on RECIST 1.1. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.

    Time frame: From date of first administration of study treatment until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression or up to approximately 26 months (as of 21 May 2012 data cut-off)

  2. Overall Survival (OS)

    OS was the length time in months from the date of first treatment until the date of death from any cause. If death was not observed, OS was censored at the last known alive date or data cut-off. Additional survival follow-up data was collected for all participants who had not withdrawn consent and were alive at the time of the initial survival follow-up as of 26 Nov 2012 data cut-off. Participants who were lost to follow-up at the time of the initial assessment may have been contacted again at the investigator's discretion. Updated survival (based on 26 Nov 2012 cut-off) was derived for these participants if the contact was made successfully.

    Time frame: From date of first administration of study treatment until the date of death, or up to approximately 32 months (as of 26 Nov 2012 data cut-off)

  3. Disease Control Rate (DCR)

    DCR was defined as the percentage of participants with BOR of CR or PR or stable disease (SD) based on RECIST 1.1 and SD lasting greater than or equal to 7 weeks, as determined by IRR and Investigator.

    Time frame: From date of first administration of study treatment until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, or up to approximately 26 months (as of 21 May 2012 data cut-off)

  4. Clinical Benefit Rate (CBR)

    CBR was defined as the percentage of participants with BOR of CR or PR or durable stable disease (dSD) \[CR + PR + dSD\] based on RECIST 1.1. The dSD rate was defined as the percentage of participants with dSD (based on RECIST 1.1 and defined as SD lasting greater than or equal to 23 weeks), as determined by the IRR and Investigator.

    Time frame: From date of first administration of study treatment until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, or up to approximately 26 months (as of 21 May 2012 data cut-off)

  5. Number of Participants With Adverse Events (AEs) /Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib Tolerability of Lenvatinib

    Safety was assessed by monitoring and recording all AEs and SAEs, regular monitoring of hematology, clinical chemistry, and urine values, regular measurement of vital signs, electrocardiograms (ECGs), and echocardiograms.

    Time frame: From the administration of first dose up to 30 days after the last dose, or up to data cut-off (21 May 2012), or up to approximately 26 months.

Other outcomes

  1. Summary of Plasma Concentration of Lenvatinib

    A total of 6 blood samples for pharmacokinetic (PK) analysis were collected from each participant who received lenvatinib once daily.

    Time frame: Predose and 2 hours postdose on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 2 Day 1

  2. Percentage Change From Baseline for the Imaging Biomarker Parameter of the Area Under the Plasma Concentration Curve Blood Normalized (90) (AUCBN (90)) Median for Total Volume

    The antiangiogenic and direct antitumor effects of lenvatinib were assessed by analyses of 2 dynamic contrast-enhanced magnetic resonance imaging/diffusion-weighted magnetic resonance imaging (DCE-MRI/DWI MRI) scans obtained on evaluable participants at Baseline and Cycle 1 Day 5. The scans were obtained using standardized acquisition across sites. DWI sequences totaling approximately 30 seconds were acquired during the DCE-MRI scans. Centralized analysis metrics for DCE-MRI included percentage change in initial area under the gadolinium contrast agent time-concentration curve (first 90 seconds, blood normalized) from baseline.

    Time frame: Cycle 1 Day 5

  3. Percentage Change From Baseline in the Contrast Volume Transfer Coefficient (Ktrans) Median

    The antiangiogenic and direct antitumor effects of lenvatinib were assessed by analyses of two DCE-MRI/DWI MRI scans obtained on evaluable participants at Baseline and Cycle 1 Day 5. The scans were obtained using standardized acquisition across sites. DWI sequences totaling approximately 30 seconds were acquired during the DCE-MRI scans. Centralized analysis metrics for DCE-MRI included the percentage change in Ktrans for gadolinium chelate movement from the vasculature into the tissue extracellular space from baseline.

    Time frame: Cycle 1 Day 5

  4. Percentage Change From Baseline in the Apparent Diffusion Coefficient (ADC) Median

    The antiangiogenic and direct antitumor effects of lenvatinib were assessed by analyses of two DCE-MRI/DWI MRI scans obtained on evaluable participants at Baseline and Cycle 1 Day 5. The scans were obtained using standardized acquisition across sites. DWI sequences totaling approximately 30 seconds were acquired during the DCE-MRI scans. Centralized analysis metrics for DCE-MRI included the percentage change in ADC for gadolinium chelate movement from the vasculature into the tissue extracellular space from baseline.

    Time frame: Cycle 1 Day 5

07

Results

Posted Apr 18, 2016

Participant flow

Participant flow — Overall Study
MilestoneLenvatinib 24 mg
Started133
Completed82
Not completed51
Withdrew: Adverse event32
Withdrew: Participant choice11
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1
Withdrew: Other6

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for target lesions assessed by magnetic resonance imaging/computed tomography (MRI/CT) scans, as determined by independent radiologic review. BOR of CR was confirmed by a subsequent CR assessment at least 4 weeks later. BOR of PR was confirmed by a subsequent CR or PR assessment at least 4 weeks later. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters. The null hypothesis ORR was ≤10% was tested using 1-sided exact test of a single proportion, at 1-sided 0.05 level. ORR was presented with corresponding 2-sided, 95% confidence interval (CI). ORR=CR+PR

Time frame:
From the date of first administration of study treatment until all participants completed a minimum of 6 cycles (28-day cycles) or discontinued treatment prior to the end of Cycle 6 (as of 21 May 2012 data cut-off)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsLenvatinib 24 mg
Objective Response Rate (ORR)14.3 (8.8 to 21.4)
SecondaryProgression Free Survival (PFS)

PFS was measured as the time from the date of first administration of study treatment until the date of first documentation of disease progression or date of death (whichever occurred first), as determined by independent radiologic review (IRR) and Investigator based on RECIST 1.1. Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions.

Time frame:
From date of first administration of study treatment until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression or up to approximately 26 months (as of 21 May 2012 data cut-off)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsLenvatinib 24 mg
Determined by IRR5.6 (3.7 to 6.3)
Determined by Investigator5.4 (3.7 to 6.7)
SecondaryOverall Survival (OS)

OS was the length time in months from the date of first treatment until the date of death from any cause. If death was not observed, OS was censored at the last known alive date or data cut-off. Additional survival follow-up data was collected for all participants who had not withdrawn consent and were alive at the time of the initial survival follow-up as of 26 Nov 2012 data cut-off. Participants who were lost to follow-up at the time of the initial assessment may have been contacted again at the investigator's discretion. Updated survival (based on 26 Nov 2012 cut-off) was derived for these participants if the contact was made successfully.

Time frame:
From date of first administration of study treatment until the date of death, or up to approximately 32 months (as of 26 Nov 2012 data cut-off)
Reported as:
Median · Months
Overall Survival (OS)
MonthsLenvatinib 24 mg
Overall Survival (OS)10.6 (8.9 to 14.9)
SecondaryDisease Control Rate (DCR)

DCR was defined as the percentage of participants with BOR of CR or PR or stable disease (SD) based on RECIST 1.1 and SD lasting greater than or equal to 7 weeks, as determined by IRR and Investigator.

Time frame:
From date of first administration of study treatment until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, or up to approximately 26 months (as of 21 May 2012 data cut-off)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsLenvatinib 24 mg
Determined by IRR60.9 (52.1 to 69.2)
Determined by Investigator66.2 (57.5 to 74.1)
SecondaryClinical Benefit Rate (CBR)

CBR was defined as the percentage of participants with BOR of CR or PR or durable stable disease (dSD) \[CR + PR + dSD\] based on RECIST 1.1. The dSD rate was defined as the percentage of participants with dSD (based on RECIST 1.1 and defined as SD lasting greater than or equal to 23 weeks), as determined by the IRR and Investigator.

Time frame:
From date of first administration of study treatment until the date of first documentation of disease progression or date of death, if death occurred prior to disease progression, or up to approximately 26 months (as of 21 May 2012 data cut-off)
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsLenvatinib 24 mg
Determined by IRR37.6 (29.3 to 46.4)
Determined by Investigator44.4 (35.8 to 53.2)
SecondaryNumber of Participants With Adverse Events (AEs) /Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib Tolerability of Lenvatinib

Safety was assessed by monitoring and recording all AEs and SAEs, regular monitoring of hematology, clinical chemistry, and urine values, regular measurement of vital signs, electrocardiograms (ECGs), and echocardiograms.

Time frame:
From the administration of first dose up to 30 days after the last dose, or up to data cut-off (21 May 2012), or up to approximately 26 months.
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) /Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Lenvatinib Tolerability of Lenvatinib
ParticipantsLenvatinib 24 mg
AEs126
SAEs62
Other pre-specifiedSummary of Plasma Concentration of Lenvatinib

A total of 6 blood samples for pharmacokinetic (PK) analysis were collected from each participant who received lenvatinib once daily.

Time frame:
Predose and 2 hours postdose on Cycle 1 Day 1, Cycle 1 Day 8, and Cycle 2 Day 1
Reported as:
Mean · ng/mL
Summary of Plasma Concentration of Lenvatinib
ng/mLLenvatinib 24 mg
Cycle 1, Day 1 (Pre-dose) n=1320 ± 0
Cycle 1, Day 1 (2-hour Post-dose) n=132318.9 ± 242.16
Cycle 1, Day 8 (Pre-dose) n=122105.6 ± 121.66
Cycle 1, Day 8 (2-hour Post-dose) n=123352.6 ± 243.88
Cycle 2, Day 1 (Pre-dose) n=10788.63 ± 78.768
Cycle 2, Day 1 (2-hour Post-dose) n=102336.8 ± 222.56
Other pre-specifiedPercentage Change From Baseline for the Imaging Biomarker Parameter of the Area Under the Plasma Concentration Curve Blood Normalized (90) (AUCBN (90)) Median for Total Volume

The antiangiogenic and direct antitumor effects of lenvatinib were assessed by analyses of 2 dynamic contrast-enhanced magnetic resonance imaging/diffusion-weighted magnetic resonance imaging (DCE-MRI/DWI MRI) scans obtained on evaluable participants at Baseline and Cycle 1 Day 5. The scans were obtained using standardized acquisition across sites. DWI sequences totaling approximately 30 seconds were acquired during the DCE-MRI scans. Centralized analysis metrics for DCE-MRI included percentage change in initial area under the gadolinium contrast agent time-concentration curve (first 90 seconds, blood normalized) from baseline.

Time frame:
Cycle 1 Day 5
Reported as:
Mean · Percentage change
Percentage Change From Baseline for the Imaging Biomarker Parameter of the Area Under the Plasma Concentration Curve Blood Normalized (90) (AUCBN (90)) Median for Total Volume
Percentage changeLenvatinib 24 mg
Percentage Change From Baseline for the Imaging Biomarker Parameter of the Area Under the Plasma Concentration Curve Blood Normalized (90) (AUCBN (90)) Median for Total Volume-34.0 ± 18.98
Other pre-specifiedPercentage Change From Baseline in the Contrast Volume Transfer Coefficient (Ktrans) Median

The antiangiogenic and direct antitumor effects of lenvatinib were assessed by analyses of two DCE-MRI/DWI MRI scans obtained on evaluable participants at Baseline and Cycle 1 Day 5. The scans were obtained using standardized acquisition across sites. DWI sequences totaling approximately 30 seconds were acquired during the DCE-MRI scans. Centralized analysis metrics for DCE-MRI included the percentage change in Ktrans for gadolinium chelate movement from the vasculature into the tissue extracellular space from baseline.

Time frame:
Cycle 1 Day 5
Reported as:
Mean · Percentage change
Percentage Change From Baseline in the Contrast Volume Transfer Coefficient (Ktrans) Median
Percentage changeLenvatinib 24 mg
Percentage Change From Baseline in the Contrast Volume Transfer Coefficient (Ktrans) Median-41.5 ± 22.02
Other pre-specifiedPercentage Change From Baseline in the Apparent Diffusion Coefficient (ADC) Median

The antiangiogenic and direct antitumor effects of lenvatinib were assessed by analyses of two DCE-MRI/DWI MRI scans obtained on evaluable participants at Baseline and Cycle 1 Day 5. The scans were obtained using standardized acquisition across sites. DWI sequences totaling approximately 30 seconds were acquired during the DCE-MRI scans. Centralized analysis metrics for DCE-MRI included the percentage change in ADC for gadolinium chelate movement from the vasculature into the tissue extracellular space from baseline.

Time frame:
Cycle 1 Day 5
Reported as:
Mean · Percentage change
Percentage Change From Baseline in the Apparent Diffusion Coefficient (ADC) Median
Percentage changeLenvatinib 24 mg
Percentage Change From Baseline in the Apparent Diffusion Coefficient (ADC) Median2.1 ± 2.27

Adverse events

Collected over From date of administration of first dose up to 30 days after the last dose, or up to data cut-off (21 May 2012), or up to approximately 26 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib 24 mg—62/133 (46.6%)125/133 (94%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventLenvatinib 24 mg
Abdominal painGastrointestinal disorders7/133
AstheniaGeneral disorders6/133
HypertensionVascular disorders6/133
DehydrationMetabolism and nutrition disorders6/133
Renal failure acuteRenal and urinary disorders6/133
VomitingGastrointestinal disorders5/133
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/133
DiarrhoeaGastrointestinal disorders4/133
HypotensionVascular disorders4/133
NauseaGastrointestinal disorders3/133
Most frequent other events
Showing 10 of 43
Most frequent other events
EventLenvatinib 24 mg
HypertensionVascular disorders71/133
FatigueGeneral disorders55/133
DiarrhoeaGastrointestinal disorders46/133
Decreased appetiteMetabolism and nutrition disorders45/133
NauseaGastrointestinal disorders41/133
HeadacheNervous system disorders35/133
Abdominal painGastrointestinal disorders33/133
VomitingGastrointestinal disorders32/133
StomatitisGastrointestinal disorders30/133
AstheniaGeneral disorders30/133

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lenvatinib 24 mg
Mean62.7 ± 8.75
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 24 mg
Female133
Male0
Prior Platinum-based Chemotherapy Regimen
Prior Platinum-based Chemotherapy Regimen(Participants)Lenvatinib 24 mg
Carboplatin80
Cisplatin47
Cisplatin w/Doxorubicin4
Taxol [Paclitaxel] w/Carboplatin10
08

Study locations

79 sites
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona, United States
  • Tucson, Arizona, United States
  • Los Angeles, California, United States
  • Honolulu, Hawaii, United States
  • Arlington Heights, Illinois, United States
  • Niles, Illinois, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Burnsville, Minnesota, United States
  • Edina, Minnesota, United States
  • Maplewood, Minnesota, United States
  • Minneapolis, Minnesota, United States
  • Saint Paul, Minnesota, United States
  • Woodbury, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Morristown, New Jersey, United States
  • New York, New York, United States
  • Chapel Hill, North Carolina, United States
  • Cleveland, North Carolina, United States
  • Durham, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • Springfield, Oregon, United States
  • Tualatin, Oregon, United States
  • Charleston, South Carolina, United States
  • Austin, Texas, United States
  • Bedford, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Tyler, Texas, United States
  • Newport News, Virginia, United States
  • Norfolk, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Vancouver, Washington, United States
  • Arlon, Belgium
  • Charleroi, Belgium
  • Duffel, Belgium
  • Ghent, Belgium
  • Kortrijk, Belgium
  • Leuven, Belgium
  • Liege, Belgium
  • Namur, Belgium
  • Oostende, Belgium
  • Roeselare, Belgium
  • Yvoir, Belgium
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Budapest, Hungary
  • Gyor, Hungary
  • Lublin, Poland
  • Poznan, Poland
  • Warsaw, Poland
  • Brasov County, Romania
  • Bucharest, Romania
  • Cluj County, Romania
  • Dolj County, Romania
  • Kazan, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • Orenburg, Russian Federation
  • Petersburg, Russian Federation
  • Pyatigorsk, Russian Federation
  • Sochi,, Russian Federation
  • St. Petersburg, Russian Federation
  • Stavropol, Russian Federation
  • Syktyvkar, Russian Federation
  • Tomsk, Russian Federation
  • Tula, Russian Federation
  • Ufa, Russian Federation
  • Vladivostok, Russian Federation
  • Chernihiv, Ukraine
  • Donetsk, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Zaporizhia, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of May 2012 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2010
First posted
Apr 27, 2010
Start
Mar 2010
Primary completionActual
May 2012
CompletionActual
Oct 2015
Results first posted
Apr 18, 2016
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01111461
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Apr 27, 2010
Start date
Mar 2010
Primary completion
May 2012
Completion
Oct 2015
Results posted
Apr 18, 2016
Last update
Jun 22, 2023

Study contacts

Eisai Medical Services
study director · Eisai Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion